Table 1 Patient clinicopathological data and HER-3 membranous and cytoplasmic expression
From: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
| Â | HER-3 membranous expression | HER-3 cytoplasmic expression | ||||
|---|---|---|---|---|---|---|
Characteristic | (+) (n= 18) | (-) (n= 88) | p | (+) (n= 30) | (-) (n= 76) | P |
Age Median (range) | 68 (53 – 75) | 63 (35 – 79) | 0.069 | 66 (52 – 76) | 61 (35 – 79) | 0.010 |
Sex | ||||||
Male | 10 (55.6%) | 56(63.6%) | 0.519 | 15 (50.0%) | 51 (67.1%) | 0.112 |
Female | 8 (44.4%) | 32(36.4%) | Â | 15 (50.0%) | 25 (32.9%) | Â |
Size | 5 (2 – 12) | 5 (1.5 – 12) | 0.959 | 5 (2 – 10) | 5 (1.5 – 12) | 0.525 |
Lymph nodes status | ||||||
(+) | 13 (72.2%) | 56(65.9%) | 0.603 | 20 (66.7%) | 49 (67.1%) | 0.964 |
(-) | 5 (27.8%) | 29(34.1%) | Â | 10 (33.3%) | 24 (32.9%) | Â |
Grade | ||||||
Well | - | 3 (3.4%) | 0.999 | - | 3 (3.9%) | 0.556 |
Moderate | 18 (100%) | 77(87.5%) | 0.205 | 30 (100.0%) | 65 (85.5%) | 0.032 |
Poor | - | 8 (18%) | 0.346 | - | 8 (10.5%) | 0.101 |
Dukes' stage | ||||||
B | 4 (22.2%) | 26(29.5%) | 0.530 | 9 (30.0%) | 21 (27.6%) | 0.807 |
C | 11 (61.1%) | 40(45.5%) | 0.226 | 14 (46.7%) | 37 (48.7%) | 0.851 |
D | 3 (16.7%) | 22(25.0%) | 0.448 | 7 (23.3%) | 18 (23.7%) | 0.969 |
Site | ||||||
Proximal colon | 4 (22.2%) | 25(28.4%) | 0.774 | 7 (23.3%) | 22 (28.9%) | 0.534 |
Distal colon | 9 (50.0%) | 28(31.8%) | 0.140 | 10 (33.3%) | 27 (35.5%) | 0.796 |
Rectum | 5 (27.8%) | 35(39.8%) | 0.339 | 13 (43.3%) | 27 (35.5%) | 0.406 |